INTRODUCTION
============

Biopharmaceuticals are indispensable in modern medicine. In 2010 more than 200 biopharmaceuticals were available on the market and around 10--20 more are approved every year ([@B94]). As the biggest group of biopharmaceuticals consists of pharmaceutical recombinant proteins, this term is often used as a synonym for the former. The biochemical and pharmacological properties of a protein are not only determined by its amino acid sequence but also largely influenced by a palette of modifications that proteins undergo co- or posttranslationally ([@B53]), usually grouped together and referred to as posttranslational modifications (PTMs). Common PTMs found in pharmaceutical proteins are glycosylation, hydroxylation, carboxylation, amidation, sulfatation, disulfide bond formation, and proteolytic processing ([@B96]). Among these, glycosylation is the most frequent PTM, being present in at least 40% of the pharmaceutical recombinant proteins available on the market ([@B95]). The presence and quality of glycosylation plays a crucial role for the pharmacological properties of a therapeutic protein by influencing protein folding and stability, serum half-life, *in vivo* activity, pharmacokinetics, and immunogenicity ([@B50]). Approximately 50% of all eukaryotic proteins are predicted to be glycosylated and this proportion increases substantially with respect to human serum proteins, which are main targets as biopharmaceuticals ([@B1]).

The workhorse for the production of simple proteins is *Escherichia coli*, the best characterized expression system offering high product yields at low costs ([@B94]). However, this microorganism is not able to perform some PTMs, which are indispensable for recombinant therapeutical proteins ([@B35]). Consequently, mammalian cell lines are the preferred expression systems for the production of recombinant glycoproteins, as their protein glycosylation patterns largely resemble those of humans ([@B77]). Among the mammalian cell lines, Chinese hamster ovary (CHO) cells comprise the leading host system for current biopharmaceuticals, even though several CHO-derived products presented non-human glycosylation ([@B10]; [@B30]; [@B58]; [@B40]).

As higher eukaryotes, plants are able to synthesize complex multimeric proteins and perform PTMs in a similar manner as humans do. Therefore, plants and plant cell cultures are gradually gaining acceptance as production hosts for recombinant biopharmaceuticals. The first plant-made pharmaceutical (PMP) received market approval in 2012 (<http://www.protalix.com/products/elelyso-taliglucerase-alfa.asp>) and several additional PMPs are being tested in clinical trials (reviewed in [@B61]). The host system for Elelyso^TM^, a recombinant glucocerebrosidase for the treatment of the lysosomal storage disease Morbus Gaucher, is a carrot-based cell line established by Protalix ([@B80]). It is cultured in bioreactors based on disposable plastic bags. While other frequently used plant systems like alfalfa, tobacco, and *Nicotiana benthamiana* need to be grown in greenhouses, bioreactor cultivation is established for the aquatic plant *Lemna minor* and for the moss *Physcomitrella patens* ([@B15]; [@B61]; [@B62]). Within the following sections we will focus on the special features for biopharmaceutical production and achievements within glyco-engineering of the moss system.

MOSS CULTIVATION AND ENGINEERING CHARACTERISTICS
================================================

The non-seed plant *P. patens*, a moss, is a well-established model system for evolutionary and functional genomics approaches ([@B11]; [@B54]; [@B56]; [@B38]; [@B71]). It can be grown throughout its complete life cycle under contained conditions *in vitro* in a simple mineral medium ([@B20]; [@B88]). The germination of the haploid spores leads to the growth of protonema (**Figure [1A](#F1){ref-type="fig"}**), a branched filamentous tissue which comprises two distinct cell types, chloronema and caulonema. Every cell is in direct contact with the culture medium, allowing efficient nutrient uptake and product secretion ([@B76]). This young tissue can be maintained in suspension cultures without any addition of phytohormones, only by mechanical disruption of the filaments. In contrast to immortalized or de-differentiated mammalian or higher-plant cell cultures, which are prone to instability or somaclonal variation ([@B47]; [@B103]; [@B2]), the fully differentiated protonema tissue is genetically stable ([@B69]). In the next developmental step, buds differentiating from protonema cells give rise to the adult plant, the leafy gametophore, consisting of shoot-like, leaf-like, and root-like tissues (**Figure [1B](#F1){ref-type="fig"}**). After fertilization of the gametes, the sporophyte, the only diploid tissue in the life cycle of mosses, grows on and is sustained by the gametophore ([@B68]). *In vitro* cultivation of all stages can be performed either on agar plates or as suspension cultures in liquid media. The availability of efficient protocols for protoplast isolation (**Figure [1C](#F1){ref-type="fig"}**) and transfection ([@B70]; [@B88]) and an excellent regeneration capacity of single transfected cells to whole plants make genetic engineering of moss a straight-forward and frequently used approach (e.g., [@B51]; [@B65]; [@B52]; [@B56]; [@B38]; [@B71]). The created moss strains can be preserved by cryo-conservation ([@B78]), and thus can serve as Master Cell Banks. The International Moss Stock Center IMSC, a reference center for moss ecotypes and transgenic lines, provides a service for long-term storage (<http://www.moss-stock-center.org>).

![***Physcomitrella patens in vitro* cultivation and schematic representation of a knockout construct for gene targeting. (A)** young filamentous tissue, protonema, ideal for suspension cultures; **(B)** adult leafy moss plant (gametophore); **(C)** protoplasts; **(D)** small scale liquid culture in flasks; **(E)** stirred tank bioreactor; **(F)** wave bioreactor (image courtesy of greenovation Biotech GmbH); **(G)** illustration of allele replacement via homologous recombination. The regions homologous to the targeted gene, which are used for the knockout construct, are shown in gray, and the inserted selection cassette is depicted in white. Thick lines represent introns and rectangles exons. Scale bars 50 μm **(A,B)**, 500 μm **(C)**.](fpls-05-00346-g001){#F1}

The employment of *in vitro* axenic plant cell or tissue cultures offers an environment in which contamination with human pathogens is rather unlikely ([@B76]). Moreover, only in these systems culture conditions can be precisely controlled and standardized ([@B28]), which is essential for the production of pharmaceuticals according to good manufacturing practice (GMP) guidelines ([@B18]).

Various scales of highly controllable cultivation devices were developed for *Physcomitrella,* ranging from simple shaking flasks (**Figure [1D](#F1){ref-type="fig"}**) and 5 L aerated flasks to diverse forms of photobioreactors, including stirred glass tank bioreactors with a volume of up to 15 L (**Figure [1E](#F1){ref-type="fig"}**; [@B27]) and a modular tubular bioreactor with a working volume of up to 100 L (reviewed in [@B16], [@B17]). More recently, disposable wave-bag reactors (**Figure [1F](#F1){ref-type="fig"}**) were employed for high-density protein production purposes under full cGMP compliance (<http://www.greenovation.com>). Several pharmaceutically interesting proteins have been synthesized in moss bioreactors, among them the growth factors vascular endothelial growth factor (VEGF; [@B4]) and erythropoietin (EPO; [@B97]) as well as the first marketed product for research use, human FGF7/keratinocyte growth factor (KGF; [www.greenovation.com](http://www.greenovation.com)). In addition, proteins with a function in immune responses like IgGs ([@B79]; [@B41]) and the complement-regulatory protein factor H ([@B7]) were produced in moss. Furthermore, two products for enzyme-replacement therapies, human alpha-galactosidase and glucocerebrosidase are expected to reach clinical trial phases by the end of 2014 ([www.greenovation.com)](http://www.greenovation.com).

The use of *Physcomitrella* as a production host for recombinant biopharmaceuticals was facilitated by well-developed molecular toolboxes. Heterologous as well as endogenous promoters were characterized for their suitability to achieve high levels of recombinant product ([@B29]; [@B98]). In addition, several moss-derived signal peptides were evaluated for improved secretion of the recombinant product to the surrounding medium ([@B72], [@B73]; [@B98]). The moss genome sequence is available since 2008 ([@B67]), and together with nearly 400,000 expressed sequence tags (ESTs) obtained from different experimental conditions, tissues, and developmental stages ([@B57]; [@B46]) it allows a reliable prediction of gene structures. The internet resource <http://www.cosmoss.org> provides access to a high-quality functional annotation including more than 32,000 protein-coding genes ([@B106]). This resource was very convenient for the identification of genes involved in the glycosylation of recombinant proteins synthesized in moss bioreactors.

However, the main driver for moss functional genomics approaches in general and glyco-engineering in particular was the unique accessibility of this organism for gene targeting approaches via homologous recombination. Displaying an exceptionally high rate of homologous recombination in mitotic cells ([@B87]; [@B74]; [@B26]; [@B36]), base-specific precise genetic engineering is feasible with high efficiency. Undesirable gene functions can be completely eliminated by targeted knockout approaches. The knockout construct used for the transfection of moss protoplasts regularly consists of 700--1000 bp genomic DNA (homologous regions) flanking each side of a selection cassette, which interrupts or replaces the target gene when indicated (**Figure [1G](#F1){ref-type="fig"}**). Glyco-engineering of moss was successfully accomplished by various gene targeting approaches (see below).

PROTEIN GLYCOSYLATION AND MOSS GLYCO-ENGINEERING
================================================

Protein glycosylation is a complex and heterogeneous modification which can be classified in two main categories, N- and O-glycosylation. In the former, the carbohydrates are attached to the amide group of asparagine (N) in the consensus sequence N-X-S/T (where X can be any amino acid except proline, and the third amino acid can be either serine or threonine; [@B55]; [@B21]). *O*-glycans, on the other hand, are attached to the hydroxyl group of serine (S), threonine (T), hydroxylysine or hydroxyproline (Hyp; [@B91]). In contrast to N-glycosylation, consensus sequences for O-glycosylation in mammals are not well defined or non-existing ([@B24]; [@B34]).

N-glycosylation in animals is a largely cell-type and species-specific feature ([@B66]; [@B13]). Moreover, potential glycosylation sites on a given protein can be either unmodified or occupied by varying glycan structures which result from the maturation of the glycan throughout the endoplasmic reticulum (ER) and the Golgi apparatus (GA), leading to microheterogeneity of glycoproteins ([@B42]). Compared to other higher eukaryotes, plants display more conserved glycan patterns between different species and a less diverse palette of *N*-glycans ([@B6]), fascilitating the production of homogeneous glycoproteins.

As higher eukaryotes, plants are able to produce *N*-glycans of the complex type with the core sugar structure Man3GlcNAc2 consisting of two *N*-acetylglucosamine and three mannose residues that is identical to humans ([@B49]; [@B101]). Up to two terminally attached GlcNAc residues are also common between plant and bi-antennary mammalian complex-type glycoprotein oligosaccharides (reviewed in [@B22]). Differing from the human structure, which displays a fucose residue 1,6-linked to the proximal GlcNAc moiety, most plant *N*-glycans carry a β1,2 xylose and an α1,3 fucose linked to the glycan core. These sugar structures are common for all land plants analyzed so far, including mosses as the evolutionary oldest group ([@B43]; [@B93]). Their presence raised concerns about plant-produced biopharmaceuticals as they were shown to induce antibody formation in mammals ([@B90]; [@B3]; [@B99]; [@B5]; [@B33]). The consequence of an immune response against the pharmaceutical can lead to antibody-mediated reduction of product efficacy as well as to severe clinical complications ([@B75]).

Consequently, first plant glyco-engineering approaches aimed at targeting the glycosyltransferases responsible for the addition of these two residues. Ten years ago *Arabidopsis thaliana* as well as moss lines lacking β1,2 xylosylation and α1,3 fucosylation have been generated ([@B44]; [@B85]). The predominant glycan type of the double knockout moss line for β1,2 xylosyltransferase (XylT) and α1,3 fucosyltransferase (FucT) was the GnGn form (GlcNAc2Man3GlcNAc2; [@B44]). A ΔXylT/FucT genotype is currently in use as genetic background for most of the recombinant products described from moss bioreactors.

Lacking the core fucose, the engineered moss *N*-glycans differ from the human ones which contain an α1,6-linked fucose residue. However, lack of this residue proved to be advantageous for the efficacy of antibodies targeting tumor cells ([@B81]; [@B83]; [@B12]; [@B79]). The underlying phenomenon, antibody-dependent cellular cytotoxicity (ADCC), comprises receptor binding and activation of a natural killer cell by an antigen--antibody complex on the target cell surface resulting in lysis of the target cell. Binding and activation of the killer cells was up to 40× more efficient with a monoclonal antibody produced in glyco-engineered, fucose-lacking moss cells compared to the same antibody produced in CHO cells ([@B79]).

In addition to the GnGn *N*-glycan form, many plant species display α1,4 fucose, and β1,3 galactose linked to the terminal GlcNAc residues on one or both of the antennae ([@B100]). This trisaccharide Fucα1-4(Galβ1-3)GlcNAc is known as Lewis A (Le^a^) structure. It is synthesized by β1,3 galactosyltransferases (GalT) and α1,4 fucosyltransferases as the last steps of *N*-glycan maturation in the plant GA (reviewed in [@B22]). In contrast to the high prevalence of xylose and core fucose residues on plant *N*-glycans, Le^a^ structures are found in a much lower proportion ([@B19]; [@B43]; [@B93]; [@B86]). However, Le^a^ epitopes were described on recombinant proteins produced in plants ([@B63]; [@B97]; [@B9]). The production of recombinant human EPO (rhEPO) in both moss and *N. benthamiana*, lead to proteins decorated with high amounts of Le^a^ structures ([@B97]; [@B9]). Although Le^a^ epitopes are found in humans as part of the Lewis-positive histo-blood groups ([@B25]), they are rarely present in healthy adults, but increased in patients with certain types of cancer ([@B105]). Furthermore, antibodies against Le^a^ epitopes are frequent ([@B102]). Therefore, it is advisable to remove the respective β1,3 galactose and α1,4 fucose residues from plant-produced recombinant products.

A single putative *α1,4 fucosyltransferase* gene was detected in the moss genome. While the targeted knockout of this gene resulted in the loss of terminal α1,4 fucose residues, β1,3-linked galactoses were still present on moss *N*-glycans. In contrast to the single-copy *α1,4 fucosyltransferase* gene, 13 putative *galt* homologs were identified in *P. patens*. Out of these, exclusively one gene (*galt1*) was shown to be responsible for the synthesis of Le^a^ in moss. The disruption of *galt1* alone resulted in the absence of the complete Le^a^ epitope, not only of the galactose residue but also of the terminal fucose, both in the total moss *N*-glycan pool and on the moss-produced rhEPO ([@B59]). The absence of the α1,4 fucose in the *galt1* knockout line (Δ*galt1*) with intact α1,4 fucosyltransferase activity confirmed that this is the last enzyme in the plant N-glycosylation pathway and that the presence of galactose on the substrate is indispensable for the fucosyltransferase activity ([@B59]). The lack of GalT1 activity did not affect the moss growth rate. The homogeneity of the rhEPO glycosylation achieved in the moss *galt1* knockout line was remarkable, with almost only one glycosylation form, the aimed core structure with terminal GlcNAc residues ([@B59]; **Figure [2](#F2){ref-type="fig"}**).

![**Glycopeptides of moss-produced rhEPO from two glyco-engineered moss lines.** Comparison of the mass spectra for the rhEPO tryptic peptide harboring two glycosylation sites (EAE[NIT]{.ul}TGCAEHCSLNE[NIT]{.ul}VPDTK) produced in glyco-engineered moss lines: double KO ΔXylT/FucT and triple KO ΔXylT/FucT/GalT (based on [@B59]). Salt adducts are marked with asterisks. The glycosylation patterns are schematized with sugar symbols above each peak. Le^a^ structures are totally absent in the triple KO line.](fpls-05-00346-g002){#F2}

In humans, the GnGn glycan is frequently further elongated with galactose added in β1,4 linkage and this is often capped with sialic acid residues. The targeted insertion ("knockin") of the human *β1,4 *galt** into the moss genome demonstrated the general feasibility of β1,4 galactosylation of moss *N*-glycans ([@B31]; [@B59]). Further terminal elongation of plant *N*-glycans has been demonstrated for *N. benthamiana* which transiently produced glycoproteins with human-like sialylation ([@B9]; [@B32]). This will be a future task for moss glyco-engineering.

Outstanding success has been achieved so far by engineering plant N-glycosylation patterns for the production of humanized glycoproteins. In contrast, the issue of adverse O-glycosylation in PMPs has not been addressed in the same detail. Concerning plant *O*-glycan engineering, recombinant proteins displaying human so-called mucin-type O-glycosylation were generated recently ([@B14]; [@B8]; [@B104]). In contrast to rather conserved N-glycosylation patterns, plant-typical O-glycosylation differs fundamentally from the typical human mucin-type O-glycosylation (reviewed by [@B22]), and was shown to induce the formation of antibodies ([@B48]). In plants, the main attachment site for O-glycosylation is 4-*trans*-Hyp (reviewed by [@B84]), while no glycosylation of Hyp occurs in animals ([@B23]). Hyp is generated posttranslationally by prolyl 4-hydroxylases (P4H) via hydroxylation of proline. Prolyl-hydroxylation is a very common modification both in mammals and in plants, though recognition sequences differ. In plants, the target motif for O-glycosylation after P4H-catalyzed hydroxylation, the so-called glycomodules present on Hyp-rich glycoproteins (HRGPs), are defined ([@B39]) and validated ([@B89]; [@B82]). *In silico* analysis of the human proteome revealed that 30% of the human proteins bear a recognition sequence for plant P4Hs ([@B22]), thus being putative candidates for non-human prolyl-hydroxylation when recombinantly produced in plant-based systems. In fact, undesired plant-typical prolyl-hydroxylation and in some cases even non-human O-glycosylation of biopharmaceuticals was reported ([@B37]; [@B97]; [@B64]). The most direct strategy to avoid non-human O-glycosylation in PMPs is the elimination of the anchor Hyp, which itself is an undesired PTM performed by plant P4H enzymes.

After systematic disruption of each of the six *p4h* genes in *Physcomitrella*, targeted deletion of *p4h1* resulted in the complete elimination of the previously reported prolyl-hydroxylation of moss-produced rhEPO ([@B60]). As prolyl-hydroxylation and further glycosylation of plant extracellular matrix and cell wall proteins play important roles for growth, cell differentiation, and stress adaption ([@B45]; [@B92]) we expected a negative impact on the growth rate of the lines. However, the Δ*p4h1* moss lines were not impaired neither in growth or development nor in protein productivity ([@B60]).

The ease of gene targeting in moss enabled glyco-engineering approaches for the elimination of any plant-typical immunogenic residues. This provides a plant-based system offering the stable production of safe protein therapeutics.
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